December 15, 2017 10:24 AM ET


Company Overview of Visterra, Inc.

Key Executives for Visterra, Inc.

NameBoard RelationshipsTitleAge
Brian J. G. Pereira M.D.20 RelationshipsChief Executive Officer, President and Director58
Alan L. Crane M.A., M.B.A.65 RelationshipsFounder and Chairman of the Board54
Ram Sasisekharan Ph.D.25 RelationshipsFounder and Director52
David A. Arkowitz 6 RelationshipsChief Financial Officer and Chief Operating Officer56
Gregory L. Miller No RelationshipsSenior Vice President of Business Development & Strategic Planning39

Visterra, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Alan L. Crane M.A., M.B.A. 65 RelationshipsVisterra, Inc.54
Brian J. G. Pereira M.D. 20 RelationshipsVisterra, Inc.58
Ram Sasisekharan Ph.D. 25 RelationshipsVisterra, Inc.52
Edwin M. Kania Jr. 69 RelationshipsFlagship Pioneering59
Akshay K. Vaishnaw M.D., Ph.D. 37 RelationshipsAlnylam Pharmaceuticals, Inc.54
View All Board Members

Visterra, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Jr.Edwin M. Kania69 Relationships3 Executives
Compensation Committee M.A., M.B.A.Alan L. Crane65 Relationships4 Executives
Nominating Committee M.D., Ph.D.Akshay K. Vaishnaw37 Relationships1 Executives
Corporate Governance Committee M.D., Ph.D.Akshay K. Vaishnaw37 Relationships1 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation
Not meaningful
Total Value of Options$516.0K
Compensation as of Fiscal Year 2016
Visterra, Inc. CEO Compensation
Industry Average


Peregrine Pharmaceuticals, Inc. Appoints Roger J. Lias, Ph.D. as Principal Executive Officer
December 14, 2017 10:00 PM ET
Gilead Sciences Announces That John C. Martin, Will Transition from Executive Chairman to Chairman of the Board of Directors, Effective March 9, 2018
December 14, 2017 9:30 PM ET
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
December 14, 2017 9:30 PM ET
Cellect Biotechnology Ltd. Announces Executive Changes
December 14, 2017 9:30 PM ET
Sangamo Therapeutics, Inc. Announces Resignation of William R. Ringo from the Board Effective January 1, 2018
December 14, 2017 9:16 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Visterra, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at